Innocan Pharma Corporation

Recent News

  • Innocan Pharma Obtains Receipt for Final Base Shelf Prospectus

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed and obtained a receipt for a final short form base shelf prospectus (the "Base Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada.The Base Shelf Prospectus allows Innocan to qualify the distribution of up to $100,000,000 of common shares, warrants, units,...

    2022-05-17 2:03 AM EDT
  • Innocan Pharma Announces the Successful Publication of a New Patent Application of Its New Sustained-Release (LPC) CBD Formulation

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - May 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that an International Patent Application ("PCT") titled "Protein-bound Cannabinoid Formulations and Uses Thereof" was recently published and received the publication number WO 2022/070191 (the "Patent Application"), claiming priority from a US provisional application filed in October 2020.The Patent Application involves a new particle-based formulation of CBD, which allows a sustained release profile...

    2022-05-11 3:00 AM EDT
  • Innocan Pharma's Compassionate Care Treatment for Dogs

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan's LPT platform) (the "Treatment"). The Treatment was administered to a 14-year-old dog suffering from severe cervical pain, hip and elbow osteoarthritis and testicular neoplasia. It was reported that the Treatment resulted in decreased pain and improved mobility. The journal,...

    2022-04-29 3:00 AM EDT
  • Innocan Pharma's Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to report the "accepted for publication" of a Case Report Article describing subcutaneously injected liposomal cannabidiol (CBD) formulation used as a compassion therapy for pain management in a dog. The final article will be published in the Frontiers Veterinary Scientific Journal, a leading and renowned journal with readership of 25M.In the Case Report a...

    2022-04-11 4:00 PM EDT
  • Innocan Pharma Reports a Successful FDA-Required Characterization of Highly CBD-Loaded Liposome Platform

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 28, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to report the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application (IND) and New Drug Application (NDA) of Innocan's liposomal...

    2022-03-28 4:00 PM EDT
  • Innocan Pharma Reports a Positive Result from the Use of Its CBD LPT on a Dog Suffering from Osteoarthritis

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 8, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that Innocan's CBD LPT injection provided as a treatment to a dog suffering from osteoarthritis of the hip and elbow joint (causing inability of the dog to walk and stand up, as well as intense pain and a low activity rate) led to a decrease in pain and improved activity and...

    2022-03-08 4:00 PM EST
  • Former Beckman Coulter Dr. Eyal Kalo to join Innocan Pharma's Expanding R&D Team

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 4, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the appointment of Dr. Eyal Kalo as Research and Development Project Manager. In this new role Dr. Eyal Kalo will coordinate internal and external R&D projects, assist in the development progress and manage the cross functional of Innocan's pharma projects. About Dr.Eyal KaloDr.Eyal Kalo earned his PhD from the Weizmann...

    2022-03-04 3:00 AM EST
  • Sony Ex-VP Dr. Kenji Kitatani to Join Innocan Pharma's Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 7, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the addition of Dr. Kenji Kitatani, a leading global media business expert, and former Executive Officer of Sony Corporation, to Innocan pharma's Advisory Committee, as an advisor to the Asian markets.The popularity of CBD products in Japan is growing rapidly. Combined with the growing admiration to natural foods, the Japanese market is...

    2022-02-07 4:36 PM EST